Oral and Systemic aMMP-8 in Periodontal Disease

Completed

• Conditions: Periodontal Diseases; Periodontal Inflammation

• Registration Number: NCT04268381
• Lead Sponsor: Aydin Adnan Menderes University

Brief Summary

Periodontal disease is an inflammatory process that can result in tooth loss and also is considered a modifying factor for systemic health. Matrix metalloproteinase (MMP)-8 is the major collagenase of periodontal tissue breakdown. The aim of the present study is to analyze active (aMMP-8) levels in gingival crevicular fluid (GCF), saliva and serum in the context of new criteria of gingivitis and stage 3 grade C periodontitis.

Detailed Description

Not available

Study Timeline

• Study Start: 2020-01-20
• Study First Submitted: 2020-02-10
• Study First Submitted QC: 2020-02-12
• Study First Posted: 2020-02-13
• Primary Completion: 2020-03-20
• Study Completion: 2020-03-20
• Status Verified: 2020-07
• Last Update Submitted: 2020-07-10
• Last Update Posted: 2020-07-14

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 83

Inclusion Criteria

• systemically healthy and non-smoker individuals aged 25 to 50 years
• having ≥20 teeth present (except third molars)
• individuals with periodontally healthy, gingivitis and stage 3 periodontitis diagnoses

Exclusion Criteria

• having any systemic disease
• smoking
• pregnancy or lactation
• using antibiotic or any anti-inflammatory drug or any periodontal treatment within the past 6 months.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Oral (GCF and saliva) and serum levels of aMMP-8 in periodontitis and gingivitis	through study completion, an average of 4 months	aMMP-8 levels

Trial Locations

Locations (1)

Aydin Adnan Menderes University; 🇹🇷 Aydın, Turkey